ASCO18
8 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by oncdoc7
Scoop.it!

American Society of Clinical Oncology

American Society of Clinical Oncology | ASCO18 | Scoop.it
The American Society of Clinical Oncology seeks to provide the highest-quality resources in education, policy, the pioneering of clinical research, and above all, advancing the care for patients with cancer.
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Nab-Paclitaxel/Gemcitabine Sustains OS in Metastatic Pancreatic Adenocarcinoma - Chemotherapy Advisor

Nab-Paclitaxel/Gemcitabine Sustains OS in Metastatic Pancreatic Adenocarcinoma - Chemotherapy Advisor | ASCO18 | Scoop.it
Nab-paclitaxel plus gemcitabine sustained overall survival rates compared with gemcitabine alone in patients with metastatic pancreatic adenocarcinoma.
oncdoc7's insight:

Abraxane125 + Gem1000 weekly x 3, 1 wk off, improved ms to 8 mths vs 6 mths, 35% 1 yr OS vs 22%.  

more...
No comment yet.
Rescooped by oncdoc7 from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Seattle Genetics: ADCETRIS® (Brentuximab Vedotin) Phase 2 Clinical Data in Diffuse Large B-cell Lymphoma (DLBCL) at ASH 2013

Of the 50 patients with DLBCL, 42 percent achieved an objective response, including 16 percent complete remissions and 26 percent partial remissions.At the time of data analysis, the median duration of response for DLBCL was 5.8 months. For DLBCL patients who achieved a complete remission, the median duration of response was 11.5 months.Objective responses were observed across a broad range of CD30 expression, from DLBCL patients with undetectable CD30 by standard immunohistochemistry testing to those with CD30 expression up to 90 percent.The most common treatment-emergent adverse events of any grade in patients with DLBCL and other B-cell lymphomas occurring in more than 25 percent of all patients enrolled were fatigue (49 percent), neutropenia (40 percent), nausea (38 percent), diarrhea (37 percent) and fever (29 percent).The most common Grade 3 treatment-emergent adverse events in patients with DLBCL and other B-cell lymphomas were neutropenia and anemia. The only Grade 4 treatment-emergent event was neutropenia. Serious adverse events considered related to treatment and occurring in more than one patient were pneumonia (three patients) and anemia, febrile neutropenia, neutropenia and thrombocytopenia (two patients each).


Via Krishan Maggon
more...
Scooped by oncdoc7
Scoop.it!

ASCO 2013 - Poster: Impact of prior docetaxel (D) on sipuleucel-T (sip-T ... - UroToday

ASCO 2013 - Poster: Impact of prior docetaxel (D) on sipuleucel-T (sip-T ...
UroToday
CHICAGO, IL USA (UroToday.com) - Presented by Celestia S. Higano,1 Andrew J. Armstrong,2 Matthew R. Cooperberg,3 Philip W.
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment - Bassan - 2016 - European Journal of Haematology - Wiley Online Library

Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment - Bassan - 2016 - European Journal of Haematology - Wiley Online Library | ASCO18 | Scoop.it
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Capecitabine/Temozolomide Emerging as a Bright New Option for Treatment-Resistant NETs

Capecitabine/Temozolomide Emerging as a Bright New Option for Treatment-Resistant NETs | ASCO18 | Scoop.it
According to the findings from a prospective phase II trial, led by principal investigator Dr. Robert L. Fine, combination therapy with capecitabine and temozolomide has proven beneficial to patients with progressive neuroendocrine tumors.
more...
No comment yet.
Rescooped by oncdoc7 from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Aplharadin to pertuzumab: Highlights of 2013's war on cancer

Aplharadin to pertuzumab: Highlights of 2013's war on cancer | ASCO18 | Scoop.it
Pertuzumab as a neoadjuvant therapy, Alpharadin for advanced prosate cancer -- these were among 2013's highlights, City of Hope experts say.

Via Krishan Maggon
more...
No comment yet.
Rescooped by oncdoc7 from Hematology
Scoop.it!

The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)

The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG) | ASCO18 | Scoop.it
The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: Study Group (GHSG) http://t.co/i93kVcCFla

Via Gilbert C FAURE
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

CRPC Challenge: Sequencing Chemotherapy With New Agents

Challenges remain regarding the mechanisms of docetaxel resistance, whether combination studies continue to make sense, and how the sequencing of docetaxel may impact toxicity and efficacy.
more...
No comment yet.